Browse our anti-CDKN1B (CDKN1B) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) Antibodies (CDKN1B)
On are 751 Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) Antibodies from 32 different suppliers available. Additionally we are shipping CDKN1B Kits (19) and CDKN1B Proteins (18) and many more products for this protein. A total of 838 CDKN1B products are currently listed.
1500011J20Rik, 2610202L11Rik, AA408329, AI843786, Bridge-1, Cdki1b, cdkn1b, cdkn1bl, CDKN4, CIB, CIBP, FAM14D, ISG12, ISG12A, Kip1, MEN1B, MEN4, P27, P27KIP1, PRKDCIP, sb:cb611, SIP2-28, wu:fb63g10, wu:fb64g10, wu:fe18e03
list all antibodies Gene Name GeneID UniProt
CDKN1B 10519 Q99828
CDKN1B 12576 P46414
CDKN1B 83571  

Show all species

Show all synonyms

All available anti-CDKN1B Antibodies

Go to our pre-filtered search.

Top referenced anti-CDKN1B Antibodies

  1. Human Polyclonal CDKN1B Primary Antibody for IHC (p), WB - ABIN389614 : Wingate, Zhang, McGarhen, Bedrosian, Harper, Keyomarsi: The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. in The Journal of biological chemistry 2005 (PubMed)
    Show all 6 references for 389614

  2. Human Polyclonal CDKN1B Primary Antibody for IHC (p), WB - ABIN389617 : Wang, Hou, Mohapatra, Ma, Cress, Pledger, Chen: Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. in The Journal of biological chemistry 2005 (PubMed)
    Show all 6 references for 389617

  3. Human Polyclonal CDKN1B Primary Antibody for EIA, IHC (p) - ABIN358183 : Kawamata, Inagaki, Mizumura, Sugimoto, Sakajiri, Ohyanagi-Hara, Oshimi: Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. in European journal of haematology 2005 (PubMed)
    Show all 5 references for 358183

  4. Human Polyclonal CDKN1B Primary Antibody for EIA, IHC (p) - ABIN358185 : Mogensen, Shaw: Current approaches to unravel the mystery of dilated cardiomyopathy, a common cause of hereditary heart failure. in Expert review of proteomics 2005 (PubMed)
    Show all 5 references for 358185

  5. Human Polyclonal CDKN1B Primary Antibody for EIA, IF - ABIN358766 : Andreu, Lledó, Poch, Ivorra, Albero, Martínez-Climent, Montiel-Duarte, Rifón, Pérez-Calvo, Arbona, Prósper, Pérez-Roger: BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. in Cancer research 2005 (PubMed)
    Show all 5 references for 358766

  6. Human Polyclonal CDKN1B Primary Antibody for ELISA, WB - ABIN1531618 : Polyak, Lee, Erdjument-Bromage, Koff, Roberts, Tempst, Massagué: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. in Cell 1994 (PubMed)

  7. Human Polyclonal CDKN1B Primary Antibody for WB - ABIN2792168 : Azzato, Driver, Lesueur, Shah, Greenberg, Easton, Teschendorff, Caldas, Caporaso, Pharoah: Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. in Breast cancer research : BCR 2008 (PubMed)

More Antibodies against CDKN1B Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) interaction partners

  1. abnormal levels of Skp2 and p27(KIP1) have probably been involved in the pathogenesis of ADH (show AVP Antibodies) and DCIS. Thus, Skp2 and p27(KIP1) may serve as important diagnosis markers.

  2. Results suggest that interaction of CIB1 with alphaIIb is one of the early events occurring during outside-in signaling. Furthermore, CIB1 recruits FAK to the alphaIIbbeta3 complex at the filopodia where FAK is activated, which in turn activates c-Src, resulting in propagation of outside-in signaling leading to platelet spreading.

  3. Cip2a (show KIAA1524 Antibodies) markedly decreased the expression and nuclear localization of p27Kip1 and this is critical for the ability of Cip2a (show KIAA1524 Antibodies) to promote Triple-negative breast cancer progression.

  4. These results indicate that the dynamic interplay between O-GlcNAcylation and cyclin dependent kinase inhibitor p27 phosphorylation coordinates and regulates cell proliferation in hepatocellular carcinoma.

  5. we found that ectopic expression of oncogenic KRas and HRas (show HRAS Antibodies) in cells resulted in elevated CIB1 (show CIB1 Antibodies) expression. We previously described the Ca(2 (show CA2 Antibodies)+)-myristoyl switch function of CIB1 (show CIB1 Antibodies), and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1 (show SPHK1 Antibodies)), a location where SK1 (show KCNN1 Antibodies) is known to elicit oncogenic signalling.

  6. Besides controlling cyclin (show PCNA Antibodies)/CDK (show CDK4 Antibodies) kinase activity, p27 (show PAK2 Antibodies) also regulates cytoskeletal dynamics, cell motility and cell invasion. Following processing by caspases, p27 (show PAK2 Antibodies) fails to bind to RhoA (show RHOA Antibodies) and to inhibit its activation, and thereby abolishes the ability of p27 (show PAK2 Antibodies) to stimulate cell migration and invasion

  7. p27 (show PAK2 Antibodies) is a key target of MDM4 (show MDM4 Antibodies) oncogenic activity in breast cancer (BC) with mutant p53 (show TP53 Antibodies).

  8. a mechanism of transcriptional regulation mediated by p27 (show PAK2 Antibodies), Pax5 (show PAX5 Antibodies), and PCAF (show KAT2B Antibodies)

  9. Our study has confirmed that altered expressions of the p16 (show CDKN2A Antibodies) and p27 (show PAK2 Antibodies) proteins might be useful biomarkers in the progression of laryngeal squamous cell carcinomas

  10. This study to analyses cytoplasmic localization of p27 (show PAK2 Antibodies) in OSCC and correlates it with prognosis. Cytoplasmic localization is associated with poor prognosis in OSCC with lymph node metastasis.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) interaction partners

  1. Study reports that p27 normally exerts a negative feedback on p21 (show D4S234E Antibodies) expression: p27 directly represses the expression of the transcription factor Pitx2 (show PITX2 Antibodies) which in turn maintains decreased p21 (show D4S234E Antibodies) levels. Consequently, in cells lacking p27, de-repression of Pitx2 (show PITX2 Antibodies) causes the up-regulation of p21 (show D4S234E Antibodies) showing a new mechanism by which p27 regulates cell cycle progression by transcriptionally regulating the expression of Pitx2 (show PITX2 Antibodies) and p21 (show D4S234E Antibodies).

  2. Fbxo7 (show FBXO7 Antibodies)-deficient immature thymocytes failed to undergo expansion in the thymus due to a lack of Cdk6 (show CDK6 Antibodies) activity, while mature T cells showed enhanced proliferative capacity upon T-cell receptor engagement due to reduced p27 levels. These studies reveal differential cell cycle regulation by Fbxo7 (show FBXO7 Antibodies) at different stages in T-cell development.

  3. systems-level control of cell cycle arrest by pRB (show PGR Antibodies)-E2F (show E2F1 Antibodies) and p27-CDK (show CDK4 Antibodies) regulation, is reported.

  4. Results demonstrated that the addition of oncogenic mutations, such as loss of p27 or p53 (show TP53 Antibodies), promotes ovarian tumor development from the benign adenomas of germ cell-deficient (show FANCL Antibodies) ovaries.

  5. p27 inactivation promotes injury islet graft loss via the elevation of proliferation and inflammatory cytokines secretion in infiltrating macrophages which induced nonspecific inflammation independent of TNF-alpha (show TNF Antibodies)/nuclear factor-kappa b pathway. T

  6. Knockout of p27 enhances arterial collateralization in response to hindlimb ischemia through enlargement of a new collateral pathway.

  7. These data illuminate a genetic pathway that initiates auditory HC regeneration and suggest p27(Kip1), GATA3 (show GATA3 Antibodies), and POU4F3 (show POU4F3 Antibodies) as additional therapeutic targets for ATOH1 (show ATOH1 Antibodies)-mediated auditory hair cells regeneration.

  8. Cdkn1b exert its effects via the inhibition of proliferation and is mediated by miR (show MLXIP Antibodies)-24 and targeted by the transcription factors FOXO4 (show FOXO4 Antibodies) and AP4 (show REPIN1 Antibodies) in the peroxidasin (Pxdn (show PXDN Antibodies)) mutation-induced eye disorders, such as glaucoma.

  9. These results suggest that fad24 (show NOC3L Antibodies) may have an important role in the S phase re-entry of quiescent C2C12 cells through the regulation of p27(Kip1) at the protein level

  10. The down-regulation of p27 and the activation of mTOR (show FRAP1 Antibodies) pathway may be involved in miR (show MLXIP Antibodies)-222-induced heart failure and autophagy inhibition.

Pig (Porcine) Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) interaction partners

  1. FoxO1a (show FOXO1 Antibodies) can regulate p27kip nuclear localization

  2. the activation of Rac1 due to the cell-cell contact plays a critical role in the transcriptional up-regulation of p27Kip1 in vascular endothelial cells.

Cow (Bovine) Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) interaction partners

  1. p27Kip1 inhibition has an effect on proliferation of bovine corneal endothelial cells by RNA interferenc

Zebrafish Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) interaction partners

CDKN1B Antigen Profile

Antigen Summary

Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1- CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry (By similarity).

Alternative names and synonyms associated with CDKN1B

  • cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) antibody
  • calcium and integrin binding 1 (calmyrin) (CIB1) antibody
  • cyclin kinase inhibitor p30 Kip1 (LOC100689401) antibody
  • cyclin-dependent kinase inhibitor 1B (Cdkn1b) antibody
  • cyclin-dependent kinase inhibitor 1B (p27, Kip1) (Cdkn1b) antibody
  • cyclin-dependent kinase inhibitor 1Ba (cdkn1ba) antibody
  • cyclin-dependent kinase inhibitor 1Bb (cdkn1bb) antibody
  • interferon, alpha-inducible protein 27 (IFI27) antibody
  • proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 (Psmd9) antibody
  • 1500011J20Rik antibody
  • 2610202L11Rik antibody
  • AA408329 antibody
  • AI843786 antibody
  • Bridge-1 antibody
  • Cdki1b antibody
  • cdkn1b antibody
  • cdkn1bl antibody
  • CDKN4 antibody
  • CIB antibody
  • CIBP antibody
  • FAM14D antibody
  • ISG12 antibody
  • ISG12A antibody
  • Kip1 antibody
  • MEN1B antibody
  • MEN4 antibody
  • P27 antibody
  • P27KIP1 antibody
  • PRKDCIP antibody
  • sb:cb611 antibody
  • SIP2-28 antibody
  • wu:fb63g10 antibody
  • wu:fb64g10 antibody
  • wu:fe18e03 antibody

Protein level used designations for CDKN1B

cyclin-dependent kinase inhibitor 1B (p27, Kip1) , cyclin-dependent kinase inhibitor 1B , DNA-PK interaction protein , DNA-PKcs-interacting protein , DNA-dependent protein kinase interacting protein , SNK-interacting protein 2-28 , calcium and integrin-binding protein 1 , Cyclin-dependent kinase inhibitor p27 , cyclin-dependent kinase inhibitor p27 , Cyclin-dependent kinase inhibitor 1B (p27 Kip1) , Cyclin-dependent kinase inhibitor 1B (p27, Kip1) , cyclin-dependent kinase inhibitor p27/Kip1 , p27Kip1 , cyclin-dependent kinase inhibitor 1b, like , kip1 , p27 , cyclin-dependent kinase inhibitor 1b (p27, kip1) , fb64g10 , 2310061N23Rik , ISG12(a) , interferon alpha-induced 11.5 kDa protein , interferon alpha-inducible protein 27, mitochondrial , interferon-stimulated gene 12a protein , 26S proteasome non-ATPase regulatory subunit 9 , 26S proteasome regulatory subunit p27

466947 Pan troglodytes
697188 Macaca mulatta
769872 Gallus gallus
100127219 Ovis aries
10519 Homo sapiens
100689401 Cricetulus griseus
12576 Mus musculus
83571 Rattus norvegicus
1027 Homo sapiens
403429 Canis lupus familiaris
374106 Gallus gallus
397584 Sus scrofa
512613 Bos taurus
100729359 Cavia porcellus
493958 Felis catus
402862 Danio rerio
368329 Danio rerio
3429 Homo sapiens
67151 Mus musculus
Selected quality suppliers for anti-CDKN1B (CDKN1B) Antibodies
Did you look for something else?